ArticleMolecular vision2012
Curcumin suppresses ovalbumin-induced allergic conjunctivitis.
Article in Molecular vision, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 52 citations in OpenAlex.
- Curcumin Supplementation (MerivaNutrients · 2022Trial
- Investigation of the effects of curcumin on serum cytokines in obese individuals: a randomized controlled trial.TheScientificWorldJournal · 2014Trial
- Olopatadine Exerts Multifaceted Protective Effects in an Ovalbumin-Induced Allergic Eye Disease Mouse Model.Bioengineering (Basel, Switzerland) · 2026Article
- Dexamethasone palmitate-loaded sHDL nanodiscs: Enhanced efficacy and safety in allergic conjunctivitis.Journal of pharmaceutical analysis · 2025Article
- Polyphenol-Loaded Nanodevices as Innovative Therapeutic Strategies for Dry Eye Disease: Advances and Perspectives.Antioxidants (Basel, Switzerland) · 2025Review
- The Role of Nutraceuticals in Age-Related Ocular Diseases.Molecules (Basel, Switzerland) · 2025Review
- A narrative literature review about alpha-lipoic acid role in dry eye and ocular surface disease.Acta ophthalmologica · 2025Review
- Curcumin in Ophthalmology: Mechanisms, Challenges, and Emerging Opportunities.Molecules (Basel, Switzerland) · 2025Review
- Biomimetic Curcumin-Loaded Liposomes for the Treatment of Dry Eyes and Meibomian Gland Dysfunction: An In Vivo Study.Journal of clinical medicine · 2024Article
- Microbiome as an endocrine organ and its relationship with eye diseases: Effective factors and new targeted approaches.World journal of gastrointestinal pathophysiology · 2024Review
- Effect of Exposure to Particulate Matter on the Ocular Surface in an Experimental Allergic Eye Disease Mouse Model.Bioengineering (Basel, Switzerland) · 2024Article
- Curcumin and chemokines: mechanism of action and therapeutic potential in inflammatory diseases.Inflammopharmacology · 2023Review
- Antioxidant Nutraceutical Strategies in the Prevention of Oxidative Stress Related Eye Diseases.Nutrients · 2023Review
- Potential Properties of Natural Nutraceuticals and Antioxidants in Age-Related Eye Disorders.Life (Basel, Switzerland) · 2022Review
- A Novel Multi-Ingredient Supplement Reduces Inflammation of the Eye and Improves Production and Quality of Tears in Humans.Ophthalmology and therapy · 2021Article
- Olive Pomace Phenolic Compounds and Extracts Can Inhibit Inflammatory- and Oxidative-Related Diseases of Human Ocular Surface Epithelium.Antioxidants (Basel, Switzerland) · 2021Article
- Ocular redness - II: Progress in development of therapeutics for the management of conjunctival hyperemia.The ocular surface · 2021Review
- Immunomodulatory Effects of Curcumin in Rheumatoid Arthritis: Evidence from Molecular Mechanisms to Clinical Outcomes.Reviews of physiology, biochemistry and pharmacology · 2021Review
- The Effect ofEvidence-based complementary and alternative medicine : eCAM · 2021Article
- A Novel Integrated Active Herbal Formulation Ameliorates Dry Eye Syndrome by Inhibiting Inflammation and Oxidative Stress and Enhancing Glycosylated Phosphoproteins in Rats.Pharmaceuticals (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAllergic conjunctivitis (AC) from an allergen-driven T helper 2 (Th2) response is characterized by conjunctival eosinophilic infiltration. Because curcumin has shown anti-allergic activity in an asthma and contact dermatitis laboratory models, we examined whether administration of curcumin could affect the severity of AC and modify the immune response to ovalbumin (OVA) allergen in an experimental AC model.
methodsMice were challenged with two doses of topical OVA via the conjunctival sac after systemic sensitization with OVA in aluminum hydroxide (ALUM). Curcumin was administered 1 h before OVA challenge. Several indicators for allergy such as serum immunoglubulin E (IgE) antibodies production, eosinophil infiltration into the conjunctiva and Th2 cytokine production were evaluated in mice with or without curcumin treatment.
resultsMice challenged with OVA via the conjunctival sac following systemic sensitization with OVA in ALUM had severe AC. Curcumin administration markedly suppressed IgE-mediated and eosinophil-dependent conjunctival inflammation. In addition, mice administered curcumin had less interleukin-4 (IL-4) and interleukin-5 (IL-5) (Th2 type cytokine) production in conjunctiva, spleen, and cervical lymph nodes than mice in the non-curcumin-administered group. OVA challenge resulted in activation of the production of inducible nitric oxide (iNOS), and curcumin treatment inhibited iNOS production in the conjunctiva.
conclusionsWe believe our findings are the first to demonstrate that curcumin treatment suppresses allergic conjunctival inflammation in an experimental AC model.
Indexed as
Identifiers
22876123PMC3413438W2118079535What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.